Patents by Inventor Paul Michael Watt
Paul Michael Watt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10288601Abstract: The present invention provides a method of determining or identifying or isolating a cell-penetrating peptide (CPP) or analog or derivative thereof having cell-type selectivity and/or at least capable of passing through a Blood Brain Barrier of an animal subject. This invention also provides CPPs and analogs and derivatives thereof, such as those set forth in SEQ ID NOs: 1-27 of the Sequence Listing, and compositions comprising one or more of the CPPs, including conjugates in which a CPP or analog or derivative thereof is linked to a cargo molecule. The invention also provides methods for transporting cargo molecules across cell membranes to specific locations within cells, and for treating, preventing and/or diagnosing diseases that are treatable by a cargo molecule to which a CPP or analog or derivative of the invention is attached. The invention also provides tailored peptide libraries for use in identifying or isolating CPPs.Type: GrantFiled: December 11, 2017Date of Patent: May 14, 2019Assignee: Phylogica LimitedInventors: Paul Michael Watt, Richard Hopkins, Katrin Hoffman
-
Publication number: 20180209960Abstract: The present invention provides a method of determining or identifying or isolating a cell-penetrating peptide (CPP) or analog or derivative thereof having cell-type selectivity and/or at least capable of passing through a Blood Brain Barrier of an animal subject. This invention also provides CPPs and analogs and derivatives thereof, such as those set forth in SEQ ID NOs: 1-27 of the Sequence Listing, and compositions comprising one or more of the CPPs, including conjugates in which a CPP or analog or derivative thereof is linked to a cargo molecule. The invention also provides methods for transporting cargo molecules across cell membranes to specific locations within cells, and for treating, preventing and/or diagnosing diseases that are treatable by a cargo molecule to which a CPP or analog or derivative of the invention is attached. The invention also provides tailored peptide libraries for use in identifying or isolating CPPs.Type: ApplicationFiled: December 11, 2017Publication date: July 26, 2018Inventors: Paul Michael Watt, Richard Hopkins, Katrin Hoffman
-
Patent number: 9880151Abstract: The present invention provides a method of determining or identifying or isolating a cell-penetrating peptide (CPP) or analog or derivative thereof having cell-type selectivity and/or at least capable of passing through a Blood Brain Barrier of an animal subject. This invention also provides CPPs and analogs and derivatives thereof, such as those set forth in SEQ ID NOs: 1-27 of the Sequence Listing, and compositions comprising one or more of the CPPs, including conjugates in which a CPP or analog or derivative thereof is linked to a cargo molecule. The invention also provides methods for transporting cargo molecules across cell membranes to specific locations within cells, and for treating, preventing and/or diagnosing diseases that are treatable by a cargo molecule to which a CPP or analog or derivative of the invention is attached. The invention also provides tailored peptide libraries for use in identifying or isolating CPPs.Type: GrantFiled: May 23, 2012Date of Patent: January 30, 2018Assignee: Phylogica LimitedInventors: Paul Michael Watt, Richard Hopkins, Katrin Hoffman
-
Publication number: 20170183374Abstract: The present invention provides the means for producing libraries of peptide structures for drug screening applications that are capable of folding or assuming their native conformations independently of artificial scaffolds or flanking sequences in the proteins from which they are derived. The libraries can be highly diverse such that they are representative of the repertoire of protein structures existing in nature. The libraries can also be non-redundant or normalized such that the bias towards specific structures existing in source data sets and/or in nature is/are removed. In a particularly preferred embodiment, the present invention provides 30,000 independent fold structures produced by this method. The present invention also provides computer-readable media and systems comprising structural data in relation to the peptide libraries, and methods for displaying and screening the libraries.Type: ApplicationFiled: December 27, 2016Publication date: June 29, 2017Inventors: Paul Michael Watt, Roland Dunbrack
-
Patent number: 9567373Abstract: The present invention provides the means for producing libraries of peptide structures for drug screening applications that are capable of folding or assuming their native conformations independently of artificial scaffolds or flanking sequences in the proteins from which they are derived. The libraries can be highly diverse such that they are representative of the repertoire of protein structures existing in nature. The libraries can also be non-redundant or normalized such that the bias towards specific structures existing in source data sets and/or in nature is/are removed. In a particularly preferred embodiment, the present invention provides 30,000 independent fold structures produced by this method. The present invention also provides computer-readable media and systems comprising structural data in relation to the peptide libraries, and methods for displaying and screening the libraries.Type: GrantFiled: September 26, 2013Date of Patent: February 14, 2017Assignee: Phylogica LimitedInventors: Paul Michael Watt, Roland Dunbrack
-
Publication number: 20150344875Abstract: The present invention provides a method for identifying a modulator or mediator of a biological activity, which activity includes antigenicity and or immunogenicity, said method comprising the step of: (i) producing a gene fragment expression library derived from defined nucleotide sequence fragments; and (ii) assaying the expression library for at least an amino acid sequence derived from step (i) for a biological activity wherein that activity is different from any activity the amino acid sequence may have in its native environment.Type: ApplicationFiled: July 9, 2015Publication date: December 3, 2015Inventors: Paul Michael Watt, Wayne Robert Thomas
-
Publication number: 20150232835Abstract: The present invention provides novel methods for producing nucleic acid fragment libraries that express highly diverse peptides or protein domains and, in particular, methods for producing nucleic acid fragment libraries wherein the nucleic acid fragments of the libraries are derived from two or more diverse characterized genomes.Type: ApplicationFiled: December 22, 2014Publication date: August 20, 2015Inventors: Paul Michael Watt, Wayne Robert Thomas, Richard Hopkins
-
Patent number: 8822409Abstract: Polypeptides are identified through an assay based on inhibiting AP-I signalling activity and others to treat acute respiratory distress syndrome (ARDS) and clinical disorders associated with the development of ARDS.Type: GrantFiled: June 20, 2008Date of Patent: September 2, 2014Assignee: Phylogica LimitedInventors: Nadia Marian Dorothy Milech, Paul Michael Watt, Patrick G. Holt, Deborah Strickland
-
Patent number: 8802634Abstract: The present invention provides compositions comprising peptidyl inhibitors of CD40L-dependent signalling that are not derived from a natural binding partner of CD40L such as CD40, or from a native CD40-CD40L interface. More particularly, the peptidyl inhibitors of the present invention are derived from natural sources that do not express CD40-CD40L costimulatory pathways. The invention also provides synthetic derivatives and analogs of the peptidyl inhibitors having enhanced binding affinity for CD40L or enhanced inhibitory activity relative to their parent molecules.Type: GrantFiled: July 13, 2009Date of Patent: August 12, 2014Assignee: Phylogica LimitedInventors: Paul Michael Watt, Richard Hopkins, Katrin Hoffman
-
Publication number: 20140141452Abstract: The present invention provides a method of determining or identifying or isolating a cell-penetrating peptide (CPP) or analog or derivative thereof having cell-type selectivity and/or at least capable of passing through a Blood Brain Barrier of an animal subject. This invention also provides CPPs and analogs and derivatives thereof, such as those set forth in SEQ ID NOs: 1-27 of the Sequence Listing, and compositions comprising one or more of the CPPs, including conjugates in which a CPP or analog or derivative thereof is linked to a cargo molecule. The invention also provides methods for transporting cargo molecules across cell membranes to specific locations within cells, and for treating, preventing and/or diagnosing diseases that are treatable by a cargo molecule to which a CPP or analog or derivative of the invention is attached. The invention also provides tailored peptide libraries for use in identifying or isolating CPPs.Type: ApplicationFiled: May 23, 2012Publication date: May 22, 2014Applicant: Phylogica LimitedInventors: Paul Michael Watt, Richard Hopkins, Katrin Hoffman
-
Publication number: 20140128268Abstract: The present invention provides the means for producing libraries of peptide structures for drug screening applications that are capable of folding or assuming their native conformations independently of artificial scaffolds or flanking sequences in the proteins from which they are derived. The libraries can be highly diverse such that they are representative of the repertoire of protein structures existing in nature. The libraries can also be non-redundant or normalized such that the bias towards specific structures existing in source data sets and/or in nature is/are removed. In a particularly preferred embodiment, the present invention provides 30,000 independent fold structures produced by this method. The present invention also provides computer-readable media and systems comprising structural data in relation to the peptide libraries, and methods for displaying and screening the libraries.Type: ApplicationFiled: September 26, 2013Publication date: May 8, 2014Applicant: Phylogica LimitedInventors: Paul Michael Watt, Roland Dunbrack
-
Patent number: 8575070Abstract: The present invention provides the means for producing libraries of peptide structures for drug screening applications that are capable of folding or assuming their native conformations independently of artificial scaffolds or flanking sequences in the proteins from which they are derived. The libraries can be highly diverse such that they are representative of the repertoire of protein structures existing in nature. The libraries can also be non-redundant or normalized such that the bias towards specific structures existing in source data sets and/or in nature is/are removed. In a particularly preferred embodiment, the present invention provides 30,000 independent fold structures produced by this method. The present invention also provides computer-readable media and systems comprising structural data in relation to the peptide libraries, and methods for displaying and screening the libraries.Type: GrantFiled: February 7, 2007Date of Patent: November 5, 2013Assignee: Phylogica LimitedInventors: Paul Michael Watt, Roland Dunbrack
-
Publication number: 20130266605Abstract: The present invention provides compositions comprising peptidyl inhibitors of CD40L-dependent signaling that are not derived from a natural binding partner of CD40L such as CD40, or from a native CD40-CD40L interface. More particularly, the peptidyl inhibitors of the present invention are derived from natural sources that do not express CD40-Cd40L costimulatory pathways. The invention also provides synthetic derivatives and analogs of the peptidyl inhibitors having enhanced binding affinity for CD40L or enhanced inhibitory activity relative to their parent molecules.Type: ApplicationFiled: September 16, 2011Publication date: October 10, 2013Applicant: PHYLOGICA LIMITEDInventors: Paul Michael Watt, Richard Hopkins, Katrin Hoffmann
-
Publication number: 20120065134Abstract: The present invention provides compositions comprising peptidyl inhibitors of CD40L-dependent signalling that are not derived from a natural binding partner of CD40L such as CD40, or from a native CD40-CD40L interface. More particularly, the peptidyl inhibitors of the present invention are derived from natural sources that do not express CD40-CD40L costimulatory pathways. The invention also provides synthetic derivatives and analogs of the peptidyl inhibitors having enhanced binding affinity for CD40L or enhanced inhibitory activity relative to their parent molecules.Type: ApplicationFiled: July 13, 2009Publication date: March 15, 2012Inventors: Paul Michael Watt, Richard Hopkins, Katrin Hoffman
-
Publication number: 20110262508Abstract: The present invention provides antimicrobial peptides and analogs thereof that are cytostatic or cytotoxic toward at least one gram-negative bacterium of the genus Acinetobacter including laboratory or clinical isolates of A. baumannii with low or non-detectable cytotoxicity against mammalian cells. Optionally, the antimicrobial peptides and analogs thereof are also cytotoxic or cytostatic against other unrelated bacteria such as Staphylococcus aureus.Type: ApplicationFiled: November 7, 2008Publication date: October 27, 2011Inventors: Paul Michael Watt, Wayne Thomas, Tatjana Katharina Heinrich
-
Publication number: 20110053831Abstract: Polypeptides are identified through an assay based on inhibiting AP-I signalling activity and others to treat acute respiratory distress syndrome (ARDS) and clinical disorders associated with the development of ARDS.Type: ApplicationFiled: June 20, 2008Publication date: March 3, 2011Inventors: Nadia Marian Dorothy Milech, Paul Michael Watt, Patrick G. Holt, Deborah Strickland
-
Patent number: 7803765Abstract: The present invention provides novel methods for producing nucleic acid fragment libraries that express highly diverse peptides or protein domains and, in particular, methods for producing nucleic acid fragment libraries wherein the nucleic acid.Type: GrantFiled: February 20, 2004Date of Patent: September 28, 2010Assignee: Phylogica LimitedInventors: Paul Michael Watt, Wayne Robert Thomas, Richard Hopkins
-
Publication number: 20100029552Abstract: The present invention provides a method for the screening of nucleic acid fragment expression libraries and selecting encoded peptides based upon their ability to modulate the activity of a target protein or nucleic acid and assume conserved conformations compatible with albeit not reiterative of the target protein or nucleic acid. The present invention also provides methods for the diagnosis and treatment of ischemia. The present invention also provides c-Jun dimerization inhibitory peptides and analogues thereof that are useful for treatment of ischemia.Type: ApplicationFiled: August 22, 2005Publication date: February 4, 2010Applicant: Phylogica LimitedInventors: Paul Michael Watt, Mark Fear
-
Publication number: 20090126724Abstract: A one-way valve (10) is disclosed which comprises a body portion (12) defining a passage through which fluid is able to pass during use, a support member (22) disposed in the passage, a seat member (28) disposed in the passage and provided with at least one aperture (32), a shaft (24) extending between the support member (22) and the seat member (28) and a membrane (26) disposed on the shaft (24) such that the membrane (26) is rotatable relative to the shaft (24). The seat member (28) cooperates with the membrane (26) such that a first predetermined pressure differential across the membrane (26) causes the membrane to cover the at least one aperture (32) and thereby prevent fluid flow past the seat member (28), and such that a second predetermined pressure differential of opposite polarity to the first predetermined pressure differential causes the membrane (26) to not cover the at least one aperture (32) and thereby permit fluid flow past the seat member (28).Type: ApplicationFiled: January 12, 2006Publication date: May 21, 2009Applicant: INFAMED LIMITEDInventors: Dennis Robert Thiele, Paul Michael Watt
-
Publication number: 20080044815Abstract: The present invention provides improved reverse hybrid assay methods for identifying amino acid residues within a protein that are required for its interaction or physical association with another protein, wherein disruption of an interaction between a protein of interest and its binding partner protein is assayed for a library of mutations of said protein of interest, and maintenance of an interaction between the protein of interest and another binding partner is assayed simultaneously in a single step, thereby reducing the incidence of uninformative mutations in the protein of interest that are detected.Type: ApplicationFiled: May 31, 2004Publication date: February 21, 2008Inventors: Paul Michael Watt, Richard Hopkins, Marie Bogoyevitch